125 related articles for article (PubMed ID: 31040163)
1. IL15-Based Trifunctional Antibody-Fusion Proteins with Costimulatory TNF-Superfamily Ligands in the Single-Chain Format for Cancer Immunotherapy.
Beha N; Harder M; Ring S; Kontermann RE; Müller D
Mol Cancer Ther; 2019 Jul; 18(7):1278-1288. PubMed ID: 31040163
[TBL] [Abstract][Full Text] [Related]
2. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy.
Kermer V; Hornig N; Harder M; Bondarieva A; Kontermann RE; Müller D
Mol Cancer Ther; 2014 Jan; 13(1):112-21. PubMed ID: 24198185
[TBL] [Abstract][Full Text] [Related]
3. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
4. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site.
Kermer V; Baum V; Hornig N; Kontermann RE; Müller D
Mol Cancer Ther; 2012 Jun; 11(6):1279-88. PubMed ID: 22491823
[TBL] [Abstract][Full Text] [Related]
5. Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format.
Fellermeier S; Beha N; Meyer JE; Ring S; Bader S; Kontermann RE; Müller D
Oncoimmunology; 2016; 5(11):e1238540. PubMed ID: 27999756
[TBL] [Abstract][Full Text] [Related]
6. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
[TBL] [Abstract][Full Text] [Related]
7. A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.
Müller D; Frey K; Kontermann RE
J Immunother; 2008 Oct; 31(8):714-22. PubMed ID: 18779748
[TBL] [Abstract][Full Text] [Related]
8. Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Kermer V; Frey K; Diebolder P; Kontermann RE; Müller D
J Immunother; 2012 Jun; 35(5):418-29. PubMed ID: 22576347
[TBL] [Abstract][Full Text] [Related]
9. Development of an antibody-ligand fusion protein scFvCD16A
Li Y; Xie S; Chen M; Li H; Wang Y; Fan Y; An K; Wu Y; Xiao W
Microb Cell Fact; 2023 Apr; 22(1):67. PubMed ID: 37041591
[TBL] [Abstract][Full Text] [Related]
10. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
Khawli LA; Hu P; Epstein AL
Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
[TBL] [Abstract][Full Text] [Related]
11. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
12. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity.
Tosic V; Thomas DL; Kranz DM; Liu J; McFadden G; Shisler JL; MacNeill AL; Roy EJ
PLoS One; 2014; 9(10):e109801. PubMed ID: 25329832
[TBL] [Abstract][Full Text] [Related]
13. Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.
Sapski S; Beha N; Kontermann RE; Müller D
Cancer Immunol Immunother; 2020 Nov; 69(11):2291-2303. PubMed ID: 32504247
[TBL] [Abstract][Full Text] [Related]
14. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
15. Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation.
Schmid AS; Neri D
PLoS One; 2019; 14(7):e0219313. PubMed ID: 31348785
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Antitumor Activity of a Recombinant IL7/IL15 Hybrid Cytokine in Mice.
Song Y; Liu Y; Hu R; Su M; Rood D; Lai L
Mol Cancer Ther; 2016 Oct; 15(10):2413-2421. PubMed ID: 27474151
[TBL] [Abstract][Full Text] [Related]
17. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
18. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
19. A novel strategy to produce high level and high purity of bioactive IL15 fusion proteins from mammalian cells.
Huang H; Luo Y; Baradei H; Liu S; Haenssen KK; Sanglikar S; Kumar S; Cini J
Protein Expr Purif; 2018 Aug; 148():30-39. PubMed ID: 29596991
[TBL] [Abstract][Full Text] [Related]
20. Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes.
Nagai H; Azuma M; Sato A; Shibui N; Ogawara S; Tsutsui Y; Suzuki A; Wakaizumi T; Ito A; Matsuyama S; Morita M; Hikosaka Kuniishi M; Ishii N; So T
Cells; 2023 Jun; 12(12):. PubMed ID: 37371066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
